Editas Medicine, Inc. (EDIT) Stock Score, Valuation & Financial Research
Editas Medicine, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for EDIT
Editas Medicine, Inc. currently has a Wall Street Score of 17/100. The stored market price is $2.79. Its financial score is 7/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Editas Medicine, Inc. does
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was
EDIT financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $2.79
- Market capitalization:
- $428.6M
- Revenue:
- $47.0M
- Net income:
- $-73.9M
- Free cash flow:
- $-165.8M
- Cash:
- $181.8M
- Total debt:
- $15.5M
- EPS:
- -0.75
- Financial score:
- 7/100
- Valuation score:
- 0/100
- Revenue score:
- 16/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-165.8M, showing cash burn in the current stored period.
- The balance sheet shows $181.8M of cash versus $15.5M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: EDIT decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 7/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research EDIT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.